Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 10090881)

1.

Actionable exomic incidental findings in 6503 participants: challenges of variant classification.

Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, Bennett JT, Crosslin DR, Ranchalis J, Jones KL, Rosenthal EA, Jarvik ER, Itsara A, Turner EH, Herman DS, Schleit J, Burt A, Jamal SM, Abrudan JL, Johnson AD, Conlin LK, Dulik MC, Santani A, Metterville DR, Kelly M, Foreman AK, Lee K, Taylor KD, Guo X, Crooks K, Kiedrowski LA, Raffel LJ, Gordon O, Machini K, Desnick RJ, Biesecker LG, Lubitz SA, Mulchandani S, Cooper GM, Joffe S, Richards CS, Yang Y, Rotter JI, Rich SS, O'Donnell CJ, Berg JS, Spinner NB, Evans JP, Fullerton SM, Leppig KA, Bennett RL, Bird T, Sybert VP, Grady WM, Tabor HK, Kim JH, Bamshad MJ, Wilfond B, Motulsky AG, Scott CR, Pritchard CC, Walsh TD, Burke W, Raskind WH, Byers P, Hisama FM, Rehm H, Nickerson DA, Jarvik GP.

Genome Res. 2015 Mar;25(3):305-15. doi: 10.1101/gr.183483.114. Epub 2015 Jan 30.

2.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

3.

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.

Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan.

4.

Barriers to cancer screening among orthodox jewish women.

Tkatch R, Hudson J, Katz A, Berry-Bobovski L, Vichich J, Eggly S, Penner LA, Albrecht TL.

J Community Health. 2014 Dec;39(6):1200-8. doi: 10.1007/s10900-014-9879-x.

PMID:
24845763
5.

Frailty Models for Familial Risk with Application to Breast Cancer.

Gorfine M, Hsu L, Parmigiani G.

J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215.

6.

Screening and early detection of pancreatic cancer in high risk population.

Chang MC, Wong JM, Chang YT.

World J Gastroenterol. 2014 Mar 7;20(9):2358-64. doi: 10.3748/wjg.v20.i9.2358. Review.

7.

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Ong FS, Das K, Wang J, Vakil H, Kuo JZ, Blackwell WL, Lim SW, Goodarzi MO, Bernstein KE, Rotter JI, Grody WW.

Expert Rev Mol Diagn. 2012 Jul;12(6):593-602. doi: 10.1586/erm.12.59. Review.

8.

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.

J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.

9.

Pancreatic cancer screening.

Shin EJ, Canto MI.

Gastroenterol Clin North Am. 2012 Mar;41(1):143-57. doi: 10.1016/j.gtc.2011.12.001. Epub 2012 Jan 5. Review.

10.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.

Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25. Erratum in: Cancer. 2014 Mar 15;120(6):927.

11.

Hereditary pancreatic cancer.

Grover S, Syngal S.

Gastroenterology. 2010 Oct;139(4):1076-80, 1080.e1-2. doi: 10.1053/j.gastro.2010.08.012. Epub 2010 Aug 19. Review. No abstract available.

12.

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Agalliu I, Gern R, Leanza S, Burk RD.

Clin Cancer Res. 2009 Feb 1;15(3):1112-20. doi: 10.1158/1078-0432.CCR-08-1822.

13.

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.

Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME.

J Clin Oncol. 2009 Jan 20;27(3):433-8. doi: 10.1200/JCO.2008.18.5546. Epub 2008 Dec 8.

14.

Validity of models for predicting BRCA1 and BRCA2 mutations.

Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM.

Ann Intern Med. 2007 Oct 2;147(7):441-50.

15.

A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services.

Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL.

Br J Cancer. 2006 Nov 20;95(10):1448-53.

16.

Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family.

Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K.

PLoS Med. 2004 Dec;1(3):e65. Epub 2004 Dec 28.

17.

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.

Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV.

J Med Genet. 2004 Jul;41(7):492-507.

18.

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).

Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL.

Breast Cancer Res. 2003;5(6):R206-16. Epub 2003 Aug 28.

19.

Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method.

Casadei S, Cortesi L, Pensotti V, Radice P, Pierotti M, Amadori D, Calistri D.

Br J Cancer. 2001 Sep 14;85(6):845-9.

20.

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.

Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E.

Br J Cancer. 2001 Feb;84(4):478-81.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk